BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 14707449)

  • 21. Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy.
    Ueda K; Terui Y; Yokoyama M; Sakajiri S; Nishimura N; Tsuyama N; Takeuchi K; Hatake K
    Leuk Lymphoma; 2013 Sep; 54(9):1928-33. PubMed ID: 23216271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma.
    Kiesewetter B; Troch M; Mayerhoefer ME; Dolak W; Simonitsch-Klupp I; Raderer M
    Oncologist; 2016 Jan; 21(1):72-5. PubMed ID: 26621040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.
    Troch M; Kiesewetter B; Willenbacher W; Willenbacher E; Zebisch A; Linkesch W; Fridrik M; Müllauer L; Greil R; Raderer M
    Haematologica; 2013 Feb; 98(2):264-8. PubMed ID: 22983582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regression of pulmonary MALT lymphoma after treatment with rituximab.
    Chong EA; Svoboda J; Cherian S; Andreadis C; Downs LH; Zhuang H; Alavi A; Tsai DE; Schuster SJ
    Leuk Lymphoma; 2005 Sep; 46(9):1383-6. PubMed ID: 16109620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
    Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
    Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP).
    Wöhrer S; Drach J; Hejna M; Scheithauer W; Dirisamer A; Püspök A; Chott A; Raderer M
    Ann Oncol; 2003 Dec; 14(12):1758-61. PubMed ID: 14630681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.
    Martinelli G; Laszlo D; Ferreri AJ; Pruneri G; Ponzoni M; Conconi A; Crosta C; Pedrinis E; Bertoni F; Calabrese L; Zucca E
    J Clin Oncol; 2005 Mar; 23(9):1979-83. PubMed ID: 15668468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of low grade gastric mucosa-associated lymphoid tissue lymphoma in stage I with Helicobacter pylori eradication. Long-term results after sequential histologic and molecular follow-up.
    Montalban C; Santon A; Boixeda D; Redondo C; Alvarez I; Calleja JL; de Argila CM; Bellas C
    Haematologica; 2001 Jun; 86(6):609-17. PubMed ID: 11418369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma.
    Pinnix CC; Gunther JR; Milgrom SA; Cruz Chamorro RJ; Medeiros LJ; Khoury JD; Amini B; Neelapu S; Lee HJ; Westin J; Fowler N; Nastoupil L; Dabaja B
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):447-455. PubMed ID: 30769175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab-induced remission of a gastric MALT lymphoma.
    Datta YH; Kampalath B; Binion DG
    Leuk Lymphoma; 2004 Jun; 45(6):1297-9. PubMed ID: 15360017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
    Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
    Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
    Bennett M; Schechter GP
    Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.
    Conconi A; Martinelli G; Thiéblemont C; Ferreri AJ; Devizzi L; Peccatori F; Ponzoni M; Pedrinis E; Dell'Oro S; Pruneri G; Filipazzi V; Dietrich PY; Gianni AM; Coiffier B; Cavalli F; Zucca E
    Blood; 2003 Oct; 102(8):2741-5. PubMed ID: 12842999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up.
    Lévy M; Copie-Bergman C; Molinier-Frenkel V; Riou A; Haioun C; Gaulard P; Delfau-Larue MH; Sobhani I; Leroy K; Delchier JC
    Leuk Lymphoma; 2010 Feb; 51(2):284-90. PubMed ID: 20038225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
    Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
    Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: preliminary data].
    Logvinenko OA; Vasil'ev VI; Sedyshev SKh; Safonova TN; Rodionova EB; Kokosadze NV; Aleksandrova EN; Cherkasova MV; Radenska-Lopovok SG; Nasonov EL
    Ter Arkh; 2012; 84(12):88-96. PubMed ID: 23479998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
    De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
    Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy.
    Celiker H; Toker E; Kaygusuz Atagunduz I
    Int Ophthalmol; 2019 Mar; 39(3):687-691. PubMed ID: 29411260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small-cell lung cancer arising after chemotherapy for a patient with lymphoma of pulmonary mucosa-associated lymphoid tissue-a case report.
    Nakao M; Oguri T; Maeno K; Kusumoto S; Ota C; Takakuwa O; Uemura T; Ozasa H; Iwashima Y; Miyazaki M; Kutsuna T; Nakamura A; Inagaki H; Sato S; Ueda R
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1711-4. PubMed ID: 19838033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.